Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Additional Considerations for HIV/HCV and OUD Comanagement and Call to Action (11 mins)
  • CME
  • CE

Credits Available
Physicians: maximum of 1.75 AMA PRA Category 1 Credits
Registered Nurses: 1.75 Nursing contact hours
Pharmacists: 1.75 contact hours (0.175 CEUs)
Released: February 6, 2020 Expiration: February 5, 2021
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
American Society of Addiction Medicine
Educational grant provided by:
Gilead Sciences
Sandra Springer, MD
Program Director
Christian Ramers Headshot
Christian B. Ramers, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Provide appropriate counsel to patients with opioid use disorder on how medication treatment for opioid use disorder affects health outcomes in patients living with HCV and/or HIV infection
  • Distinguish between key characteristics of FDA-approved medications for treating opioid use disorder when considering the most appropriate option for each patient
  • Implement strategies to effectively comanage substance use disorder with HCV and/or HIV infection

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Sandra Springer, MD

Associate Professor of Medicine
Division of Infectious Disease
Department of Internal Medicine
Yale School of Medicine
New Haven, Connecticut
Attending Physician
Section of Infectious Disease
Department of Internal
Medicine
Veterans Administration Connecticut Healthcare Services
West Haven, Connecticut

Sandra Springer, MD, has disclosed that she has received consulting fees from Alkermes Inc. and DKB Med and fees for non-CME/CE services from DKB Med.

Faculty

Christian B. Ramers, MD, MPH

Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California

Christian B. Ramers, MD, MPH, has disclosed that he has received fees for non-CME/CE services from AbbVie, Gilead Sciences, Merck, and ViiV Healthcare; consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; and funds for research support from AbbVie and Gilead Sciences.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra D. Cravens, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with opioid addiction and HCV and/or HIV infection.

Goal

The goal of this activity is to improve participants’ competence in achieving key clinical outcomes of diagnosis, linkage to care, and successful treatment in patients with opioid addiction and HCV and/or HIV infection.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.75 contact hour.

Pharmacist Continuing Education

Credit Designation

CCO designates this continuing education activity for 1.75 contact hour (0.175 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-023-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 06, 2020, through February 05, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Additional Considerations for HIV/HCV and OUD Comanagement and Call to Action (11 mins)
  • CME
  • CE

Assess a series of important considerations for comanagement of HIV/HCV infection and opioid use disorder (OUD), including the high level of compatibility between HIV and/or HCV treatment regimens and medications for the treatment of OUD, the impact of comorbid stimulant use among patients with OUD, recognition of OUD as a chronic relapsing disorder that often requires treatment reinitiation, and the challenges of pain management for individuals with OUD.
Sandra Springer, MD
Program Director
Christian Ramers Headshot
Christian B. Ramers, MD, MPH
Physicians: maximum of 1.75 AMA PRA Category 1 Credits
Registered Nurses: 1.75 Nursing contact hours
Pharmacists: 1.75 contact hours (0.175 CEUs)
Released: February 6, 2020 Expiration: February 5, 2021

This program is divided into several short segments which you can step through using the Video Chapters widget.

Related Content

In this CCO commentary, Drs. Chinazo Cunningham and Tiffany Lu outline how HCV and HIV clinicians can integrate OUD care into their clinical practice

Chinazo Cunningham, MD, MS Tiffany Lu, MD, MS Released: October 22, 2020

Downloadable slides from CCO expert, Dr. Alain H. Litwin, on integrating HCV and HIV prevention and care strategies into addiction care settings

Alain H. Litwin, MD Released: September 18, 2020

CCO commentary by Dr. Jenna Butner on the importance of and strategies for incorporating HIV risk counseling into substance use disorder care

Jenna Butner, MD Released: August 24, 2020

Expert guidance on screening and medication treatment for opioid use disorder (OUD) in HIV and other infectious disease practice settings, from CCO

Sandra Springer, MD Released: June 25, 2020

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
American Society of Addiction Medicine
Educational grant provided by:
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue